García Rodríguez C, López Trascasa M, Ferreira Cerdán A, Fontán Casariego G
Departamento de Laboratorio, Hospital La Paz, Madrid.
An Esp Pediatr. 1987 Dec;27(6):411-5.
Thirty five patients affected by primary immunodeficiency diseases were treated with a polyethylenglicol treated intravenous gammaglobulin. Number of infusions administered during a period of 665 months/patients, was 110. In those cases previously treated with intramuscular gammaglobulin, serum IgG levels were higher after intravenous gammaglobulin administration. Therapeutic response was favourable in most cases. Intravenous gammaglobulin was well tolerated, noticing only two serious and two mild adverse reactions. Patients that suffered adverse reactions with intramuscular gammaglobulin tolerated well intravenous preparation used, except for one patient that after two years in treatment developed IgE mediated antibodies against IgA. Need of an individualized dosage is emphasized.
35例原发性免疫缺陷病患者接受了聚乙二醇处理的静脉注射丙种球蛋白治疗。在665个患者月的时间段内进行的输注次数为110次。在先前接受过肌肉注射丙种球蛋白治疗的病例中，静脉注射丙种球蛋白后血清IgG水平更高。大多数病例的治疗反应良好。静脉注射丙种球蛋白耐受性良好，仅出现2例严重和2例轻度不良反应。在肌肉注射丙种球蛋白时出现不良反应的患者对所使用的静脉制剂耐受性良好，但有1例患者在治疗两年后产生了针对IgA的IgE介导抗体。强调了个体化剂量的必要性。
